Aditya H Gaur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5573143/publications.pdf

Version: 2024-02-01

107 papers	5,214 citations	38 h-index	95266 68 g-index
110	110	110	6871 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Host Predictors of Broadly Cross-Reactive Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern Differ Between Infection and Vaccination. Clinical Infectious Diseases, 2022, 75, e705-e714.	5.8	10
2	An adaptive, asymptomatic SARS-CoV-2 workforce screening program providing real-time, actionable monitoring of the COVID-19 pandemic. PLoS ONE, 2022, 17, e0268237.	2.5	3
3	PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2. MSphere, 2022, 7, e0017922.	2.9	25
4	Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development. EBioMedicine, 2022, 80, 104065.	6.1	4
5	A nucleic acid amplification testâ€based strategy does not help inform return to work for healthcare workers with COVIDâ€19. Influenza and Other Respiratory Viruses, 2022, 16, 851-853.	3.4	1
6	Randomized Controlled Trial of a Remote Coaching mHealth Adherence Intervention in Youth Living with HIV. AIDS and Behavior, 2022, 26, 3897-3913.	2.7	5
7	Modeling Adherence Interventions Among Youth with HIV in the United States: Clinical and Economic Projections. AIDS and Behavior, 2021, 25, 2973-2984.	2.7	5
8	Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. Journal of Infectious Diseases, 2021, 224, 1581-1592.	4.0	72
9	Qualitative Study on the Acceptability of and Adherence to a Vaginal Ring for HIV Prophylaxis Among Adolescent Girls. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 944-950.	2.1	2
10	Correlates of High HIV Viral Load and Antiretroviral Therapy Adherence Among Viremic Youth in the United States Enrolled in an Adherence Improvement Intervention. AIDS Patient Care and STDs, 2021, 35, 145-157.	2.5	3
11	High Prevalence of Anal High-Grade Squamous Intraepithelial Lesions, and Prevention Through Human Papillomavirus Vaccination, in Young Men Who Have Sex With Men Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, 1388-1396.	5.8	17
12	Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. JAMA - Journal of the American Medical Association, 2021, 325, 2500.	7.4	83
13	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. New England Journal of Medicine, 2021, 385, 595-608.	27.0	359
14	Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy. Open Forum Infectious Diseases, 2021, 8, ofab420.	0.9	12
15	Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. The Lancet Child and Adolescent Health, 2021, 5, 642-651.	5.6	10
16	Preventing Medication Nonadherence of Youth (13–24ÂYears) With HIV Initiating Antiretroviral Therapy. Journal of Adolescent Health, 2021, 69, 644-652.	2.5	2
17	An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization. Microbiology Spectrum, 2021, 9, e0105921.	3.0	14
18	Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age. Clinical Infectious Diseases, 2020, 71, 1281-1288.	5.8	10

#	Article	IF	CITATIONS
19	Mucosal barrier injury–associated bloodstream infections in pediatric oncology patients. Pediatric Blood and Cancer, 2020, 67, e28234.	1.5	15
20	Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 135-139.	2.1	20
21	Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. Lancet Infectious Diseases, The, 2020, 20, 964-975.	9.1	47
22	Liver Enzyme Elevations in Plasmodium falciparum Volunteer Infection Studies: Findings and Recommendations. American Journal of Tropical Medicine and Hygiene, 2020, 103, 378-393.	1.4	20
23	Outcomes after bloodstream infection in hospitalized pediatric hematology/oncology and stem cell transplant patients. Pediatric Blood and Cancer, 2019, 66, e27978.	1.5	18
24	Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men. Papillomavirus Research (Amsterdam, Netherlands), 2019, 7, 52-61.	4.5	17
25	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for ⟨i⟩CYP2B6⟨/i⟩ and Efavirenz ontaining Antiretroviral Therapy. Clinical Pharmacology and Therapeutics, 2019, 106, 726-733.	4.7	125
26	Discontinuity in Medicaid Coverage Among Young Adults with HIV. AIDS Patient Care and STDs, 2019, 33, 89-92.	2.5	0
27	Interest of Youth Living With HIV in Long-Acting Antiretrovirals. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 190-197.	2.1	48
28	Uptake and virological outcomes of single―versus multiâ€ŧablet antiretroviral regimens among treatmentâ€naà ve youth in the <scp>HIV</scp> Research Network. HIV Medicine, 2019, 20, 169-174.	2.2	9
29	Triggered Escalating Real-Time Adherence Intervention to Promote Rapid HIV Viral Suppression Among Youth Living With HIV Failing Antiretroviral Therapy: Protocol for a Triggered Escalating Real-Time Adherence Intervention. JMIR Research Protocols, 2019, 8, e11416.	1.0	12
30	Model-Based Methods to Translate Adolescent Medicine Trials Network for HIV/AIDS Interventions Findings Into Policy Recommendations: Rationale and Protocol for a Modeling Core (ATN 161). JMIR Research Protocols, 2019, 8, e9898.	1.0	6
31	A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital. Vaccine, 2018, 36, 214-219.	3.8	13
32	Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5
33	Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation. JAMA - Journal of the American Medical Association, 2018, 320, 995.	7.4	136
34	Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. Lancet Infectious Diseases, The, 2018, 18, 854-863.	9.1	43
35	The impact of the <i>UGT1A1*60</i> allele on bilirubin serum concentrations. Pharmacogenomics, 2017, 18, 5-16.	1.3	4
36	Use of Placebo Pills Before Treatment Initiation in Youth with HIV: Are They Ready?. Journal of the International Association of Providers of AIDS Care, 2017, 16, 412-417.	1.5	2

3

#	Article	IF	CITATIONS
37	A Prospective, Holistic, Multicenter Approach to Tracking and Understanding Bloodstream Infections in Pediatric Hematology-Oncology Patients. Infection Control and Hospital Epidemiology, 2017, 38, 690-696.	1.8	23
38	Body Image and Risk Behaviors in Youth with HIV. AIDS Patient Care and STDs, 2017, 31, 176-181.	2.5	2
39	Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia. Clinical Infectious Diseases, 2017, 65, 1790-1798.	5.8	62
40	Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clinical Infectious Diseases, 2017, 65, 1819-1828.	5.8	179
41	Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. The Lancet Child and Adolescent Health, 2017, 1, 27-34.	5.6	22
42	Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. Journal of Clinical Oncology, 2017, 35, 2082-2094.	1.6	337
43	Central Line Associated Blood Stream Infections in Pediatric Hematology/Oncology Patients With Different Types of Central Lines. Pediatric Blood and Cancer, 2016, 63, 1603-1607.	1.5	54
44	Antimicrobial Stewardship Barriers and Goals in Pediatric Oncology and Bone Marrow Transplantation: A Survey of Antimicrobial Stewardship Practitioners. Infection Control and Hospital Epidemiology, 2016, 37, 343-347.	1.8	39
45	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>UGT1A1</i> and Atazanavir Prescribing. Clinical Pharmacology and Therapeutics, 2016, 99, 363-369.	4.7	161
46	Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV,the, 2016, 3, e561-e568.	4.7	30
47	The Impact of Youth-Friendly Structures of Care on Retention Among HIV-Infected Youth. AIDS Patient Care and STDs, 2016, 30, 170-177.	2.5	42
48	Characterizing Body Image in Youth with HIV. AIDS and Behavior, 2016, 20, 1585-1590.	2.7	6
49	Burden of bloodstream infections among ambulatory pediatric hematology/oncology patients with a central line Journal of Clinical Oncology, 2016, 34, 262-262.	1.6	0
50	The Impact of Vaccine Concerns on Racial/Ethnic Disparities in Influenza Vaccine Uptake Among Health Care Workers. American Journal of Public Health, 2015, 105, e35-e41.	2.7	26
51	Effective Treatment of Cerebral Mucormycosis Associated with Brain Surgery. Pediatric Infectious Disease Journal, 2015, 34, 542-543.	2.0	7
52	Aging and Loss to Follow-up Among Youth Living With Human Immunodeficiency Virus in the HIV Research Network. Journal of Adolescent Health, 2015, 56, 345-351.	2.5	64
53	Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children. Vaccine Journal, 2015, 22, 298-303.	3.1	34
54	A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1–infected Children With Virologic Suppression. Pediatric Infectious Disease Journal, 2015, 34, 376-382.	2.0	16

#	Article	IF	CITATIONS
55	The HIV Care Continuum: Changes over Time in Retention in Care and Viral Suppression. PLoS ONE, 2015, 10, e0129376.	2.5	56
56	Preventing CLABSIs Among Pediatric Hematology/Oncology Inpatients: National Collaborative Results. Pediatrics, 2014, 134, e1678-e1685.	2.1	89
57	Prospective evaluation for respiratory pathogens in children with sickle cell disease and acute respiratory illness. Pediatric Blood and Cancer, 2014, 61, 507-511.	1.5	14
58	Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Cancer, 2014, 120, 1985-1992.	4.1	53
59	Trends in Hospitalizations Among Children and Young Adults with Perinatally Acquired HIV. Pediatric Infectious Disease Journal, 2014, 33, 488-494.	2.0	17
60	Pause, Listen, Share. JAMA - Journal of the American Medical Association, 2014, 312, 345.	7.4	4
61	The Use of Cell Phone Support for Non-adherent HIV-Infected Youth and Young Adults: An Initial Randomized and Controlled Intervention Trial. AIDS and Behavior, 2014, 18, 686-696.	2.7	95
62	PG4KDS: A model for the clinical implementation of preâ€emptive pharmacogenetics. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 45-55.	1.6	221
63	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation. Clinical Pharmacology and Therapeutics, 2013, 94, 207-210.	4.7	164
64	Surveillance of Hospital-Acquired Central Line–Associated Bloodstream Infections in Pediatric Hematology-Oncology Patients Lessons Learned, Challenges Ahead. Infection Control and Hospital Epidemiology, 2013, 34, 315-320.	1.8	17
65	Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Pediatric Infectious Disease Journal, 2013, 32, i.	2.0	46
66	Conformity of Pediatric/Adolescent HIV Clinics to the Patient-Centered Medical Home Care Model. AIDS Patient Care and STDs, 2013, 27, 272-279.	2.5	13
67	Delayed Entry into and Failure to Remain in HIV Care Among HIV-Infected Adolescents. AIDS Research and Human Retroviruses, 2013, 29, 99-104.	1.1	30
68	Prechewing and Prewarming Food for HIV-Exposed Children: A Prospective Cohort Experience from Latin America. AIDS Patient Care and STDs, 2013, 27, 142-145.	2.5	5
69	Optimizing Frequency of CD4 Assays in the Era of Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2013, 29, 418-422.	1.1	1
70	Evaluating Application of the National Healthcare Safety Network Central Line—Associated Bloodstream Infection Surveillance Definition: A Survey of Pediatric Intensive Care and Hematology/Oncology Units. Infection Control and Hospital Epidemiology, 2013, 34, 663-670.	1.8	23
71	Prospective Detection of Respiratory Pathogens in Symptomatic Children With Cancer. Pediatric Infectious Disease Journal, 2013, 32, e99-e104.	2.0	37
72	Premastication as a Route of Pediatric HIV Transmission. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 207-212.	2.1	29

#	Article	IF	CITATIONS
73	Predictors of Highly Active Antiretroviral Therapy Utilization for Behaviorally HIV-1–Infected Youth: Impact of Adult Versus Pediatric Clinical Care Site. Journal of Adolescent Health, 2012, 50, 471-477.	2.5	26
74	Guideline for the Management of Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2012, 30, 4427-4438.	1.6	311
75	Psychological Factors, Beliefs About Medication, and Adherence of Youth With Human Immunodeficiency Virus in a Multisite Directly Observed Therapy Pilot Study. Journal of Adolescent Health, 2011, 48, 637-640.	2.5	23
76	Motivating factors for high rates of influenza vaccination among healthcare workers. Vaccine, 2011, 29, 5963-5969.	3.8	74
77	Incidence of and risk factors for community acquired pneumonia in US HIV-infected children, 2000–2005. Aids, 2011, 25, 717-720.	2.2	14
78	Initial Management of Fever and Neutropenia in a Child With Cancerâ€"The Past, the Present, and the Future. Clinical Pediatric Emergency Medicine, 2011, 12, 174-184.	0.4	3
79	Severe H1N1â€associated acute respiratory failure in immunocompromised children. Pediatric Blood and Cancer, 2011, 57, 625-628.	1.5	14
80	Disparities in Antiretroviral Treatment: A Comparison of Behaviorally HIV-Infected Youth and Adults in the HIV Research Network. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 100-107.	2.1	29
81	Knowledge and Practice of Prechewing/Prewarming Food by HIV-Infected Women. Pediatrics, 2011, 127, e1206-e1211.	2.1	11
82	Antiretroviral Therapy in HIV-Infected Infants and Children. Pediatric Infectious Disease Journal, 2010, 29, 360-363.	2.0	4
83	Directly Observed Therapy (DOT) for Nonadherent HIV-Infected Youth: Lessons Learned, Challenges Ahead. AIDS Research and Human Retroviruses, 2010, 26, 947-953.	1.1	23
84	Intravenous Zanamivir for Oseltamivir-Resistant 2009 H1N1 Influenza. New England Journal of Medicine, 2010, 362, 88-89.	27.0	128
85	The Use and Abuse of Antibiotics and the Development of Antibiotic Resistance. Advances in Experimental Medicine and Biology, 2010, 659, 73-82.	1.6	87
86	Risk Prediction in Pediatric Cancer Patients With Fever and Neutropenia. Pediatric Infectious Disease Journal, 2010, 29, 53-59.	2.0	66
87	Practice of Feeding Premasticated Food to Infants: A Potential Risk Factor for HIV Transmission. Pediatrics, 2009, 124, 658-666.	2.1	74
88	Implementation of and Barriers to Routine HIV Screening for Adolescents. Pediatrics, 2009, 124, 1076-1084.	2.1	54
89	Development of a Directly Observed Therapy Adherence Intervention for Adolescents with Human Immunodeficiency Virus–1: Application of Focus Group Methodology to Inform Design, Feasibility, and Acceptability. Journal of Adolescent Health, 2009, 44, 124-132.	2.5	17
90	Etiology and Clinical Course of Febrile Neutropenia in Children With Cancer. Journal of Pediatric Hematology/Oncology, 2009, 31, 623-629.	0.6	145

#	Article	IF	CITATIONS
91	Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine, 2008, 26, 6883-6893.	3.8	38
92	Risk Factors for Severe Respiratory Syncytial Virus Disease in Children With Cancer: The Importance of Lymphopenia and Young Age. Pediatrics, 2008, 121, 235-243.	2.1	172
93	Early Archiving and Predominance of Nonnucleoside Reverse Transcriptase Inhibitor–Resistant HIVâ€1 among Recently Infected Infants Born in the United States. Journal of Infectious Diseases, 2007, 195, 1402-1410.	4.0	58
94	LEGIONELLA BOZEMANII PULMONARY ABSCESS IN A PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT RECIPIENT. Pediatric Infectious Disease Journal, 2007, 26, 760-762.	2.0	17
95	Does It Really Take Longer Not to Prescribe Antibiotics for Viral Respiratory Tract Infections in Children?. Academic Pediatrics, 2006, 6, 152-156.	1.7	28
96	The judicious use of antibiotics—An investment towards optimized health care. Indian Journal of Pediatrics, 2006, 73, 343-350.	0.8	21
97	Diagnosis of Catheter-Related Bloodstream Infections Among Pediatric Oncology Patients Lacking a Peripheral Culture, Using Differential Time to Detection. Pediatric Infectious Disease Journal, 2005, 24, 445-449.	2.0	66
98	Infections in children and young adults with bone malignancies undergoing limb-sparing surgery. Cancer, 2005, 104, 602-610.	4.1	37
99	Provider and Practice Characteristics Associated With Antibiotic Use in Children With Presumed Viral Respiratory Tract Infections. Pediatrics, 2005, 115, 635-641.	2.1	51
100	Optimum management of pediatric patients with fever and neutropenia. Indian Journal of Pediatrics, 2004, 71, 825-835.	0.8	18
101	In Situ Diagnosis of Central Venous Catheter-Related Bloodstream Infection Without Peripheral Blood Culture. Pediatric Infectious Disease Journal, 2004, 23, 614-618.	2.0	52
102	Difference in Time to Detection: A Simple Method to Differentiate Catheter-Related from Nonâ€"Catheter-Related Bloodstream Infection in Immunocompromised Pediatric Patients. Clinical Infectious Diseases, 2003, 37, 469-475.	5.8	80
103	Catheter Design Influences Recurrence of Catheter-Related Bloodstream Infection in Children With Cancer. Journal of Clinical Oncology, 2003, 21, 3520-3525.	1.6	55
104	Optimizing blood culture practices in pediatric immunocompromised patients: evaluation of media types and blood culture volume. Pediatric Infectious Disease Journal, 2003, 22, 545-552.	2.0	31
105	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, 545-552.	2.0	20
106	Bacillus cereus Bacteremia and Meningitis in Immunocompromised Children. Clinical Infectious Diseases, 2001, 32, 1456-1462.	5.8	147
107	THE EXPANDING SPECTRUM OF DISEASES CAUSED BY BACILLUS CEREUS. Pediatric Infectious Disease Journal, 2001, 20, 533-534.	2.0	25